Evidence map›Paper›PMID 24649314›Full record

ArticleMolecular and clinical oncology2014

Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.

Lin Yang, Yi Yang, Qiong Qin, Aiping Zhou, Jianjun Zhao, Jinwan Wang, Chang Shu, Xinghua Yuan, Songnian Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Emerging role of S-1 in gastric cancer.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lin YangCancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021;
Yi YangBeijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, P.R. China.
Qiong QinCancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021;
Aiping ZhouCancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021;
Jianjun ZhaoCancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021;
Jinwan WangCancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021;
Chang ShuBeijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, P.R. China.
Xinghua YuanCancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021;
Songnian HuBeijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is the fourth most common type of cancer, accounting for an estimated one million new cases annually worldwide. Locally advanced GC often recurs, even following curative surgical resection. Therefore, there is a need for an effective adjuvant chemotherapy regimen. The aim of this trial was to investigate the maximum tolerated dose (MTD) of S-1 when administered in combination with oxaliplatin in postoperative GC patients. Oxaliplatin was administered at a fixed dose of 130 mg/m

Indexed as

adjuvant chemotherapycytochrome P450 2A6maximum-tolerated doseoxaliplatinS-1

Identifiers

PMID24649314
PMCPMC3915807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.